Back to Search Start Over

MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint.

Authors :
Olaru AV
Ghiaur G
Yamanaka S
Luvsanjav D
An F
Popescu I
Alexandrescu S
Allen S
Pawlik TM
Torbenson M
Georgiades C
Roberts LR
Gores GJ
Ferguson-Smith A
Almeida MI
Calin GA
Mezey E
Selaru FM
Source :
Hepatology (Baltimore, Md.) [Hepatology] 2011 Dec; Vol. 54 (6), pp. 2089-98.
Publication Year :
2011

Abstract

Unlabelled: MicroRNAs (miRs) recently emerged as prominent regulators of cancer processes. In the current study we aimed at elucidating regulatory pathways and mechanisms through which miR-494, one of the miR species found to be down-regulated in cholangiocarcinoma (CCA), participates in cancer homeostasis. miR-494 was identified as down-regulated in CCA based on miR arrays. Its expression was verified with quantitative real-time reverse-transcription polymerase chain reaction (qRT-PCR). To enforce miR expression, we employed both transfection methods, as well as a retroviral construct to stably overexpress miR-494. Up-regulation of miR-494 in cancer cells decreased growth, consistent with a functional role. mRNA arrays of cells treated with miR-494, followed by pathway analysis, suggested that miR-494 impacts cell cycle regulation. Cell cycle analyses demonstrated that miR-494 induces a significant G1/S checkpoint reinforcement. Further analyses demonstrated that miR-494 down-regulates multiple molecules involved in this transition checkpoint. Luciferase reporter assays demonstrated a direct interaction between miR-494 and the 3'-untranslated region of cyclin-dependent kinase 6 (CDK6). Last, xenograft experiments demonstrated that miR-494 induces a significant cancer growth retardation in vivo.<br />Conclusion: Our findings demonstrate that miR-494 is down-regulated in CCA and that its up-regulation induces cancer cell growth retardation through multiple targets involved in the G1-S transition. These findings support the paradigm that miRs are salient cellular signaling pathway modulators, and thus represent attractive therapeutic targets. miR-494 emerges as an important regulator of CCA growth and its further study may lead to the development of novel therapeutics.<br /> (Copyright © 2011 American Association for the Study of Liver Diseases.)

Details

Language :
English
ISSN :
1527-3350
Volume :
54
Issue :
6
Database :
MEDLINE
Journal :
Hepatology (Baltimore, Md.)
Publication Type :
Academic Journal
Accession number :
21809359
Full Text :
https://doi.org/10.1002/hep.24591